Biocardia stock.

Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000.BioCardia has received a go-ahead from the FDA for a first-in-human trial of a second version of its stem cell implants designed to help rescue patients from heart failure. The green light clears ...BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart F. Find the latest BioCardia, Inc. (BCDA) stock quote, …Richard has made over 43 trades of the BioCardia stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of BCDA stock worth $14,600 on 17 June 2019.Nov 17, 2023 · Source. Headline. Genocea Biosciences (NASDAQ:GNCAQ) vs. BioCardia (NASDAQ:BCDA) Financial Analysis. americanbankingnews.com - November 17 at 1:30 AM. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. finance.yahoo.com - November 16 at 3:00 PM.

Get the latest BioCardia, Inc. (BCDA) stock news and headlines to help you in your trading and investing decisions. ... 2023 BioCardia, Inc. reports earnings inline with expectations. Reported EPS ...BioCardia stock rises on FDA nod to start trial of stem cell therapy for heart failure Dec. 06, 2022 8:33 AM ET BioCardia, Inc. (BCDA) By: Ravikash , SA News Editor 1 Comment Sarah Silbiger

FORM OF. SECURITIES PURCHASE AGREEMENT. This Securities Purchase Agreement (this "Agreement") is dated as of November 16, 2023, between BioCardia, Inc., a Delaware corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" …The latest update sent BioCardia’s stock down around 20% to 62 cents in premarket trading, adding to losses that have seen the share price slide by more than 60% in six months.

Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last recorded price of $0.42.BioCardia Stock Down 10.0 %. NASDAQ BCDA opened at $0.72 on Tuesday. The stock has a market capitalization of $15.59 million, a P/E ratio of -1.16 and a beta of 1.29. BioCardia has a 52-week low of $0.36 and a 52-week high of $2.92. The firm has a 50-day moving average price of $0.44 and a 200 day moving average price of $1.26.Nov 16, 2023 · "Subsidiary" shall have the meaning ascribed to such term in Section 3.1(a). "Trading Day" means a day on which the principal Trading Market is open for trading. "Trading Market" means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq ... BioCardia (BCDA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright remains neutral on the stock and ...

BioCardia, Inc. Common Stock (BCDA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27% Nov-15-23 …

BioCardia Stock Price, News & Analysis (NASDAQ:BCDA) $0.63 -0.05 (-7.35%) (As of 12:50 PM ET) Compare Today's Range $0.62 $0.69 50-Day Range $0.37 …BioCardia stock has received a consensus rating of buy. The average rating score is and is based on 9 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for BioCardia stock? 6 hari yang lalu ... GlobeNewswire. BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data ...BioCardia (BCDA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright remains neutral on the stock and ...Exhibit 4.1 [Director Deferred Settlement—Fixed Date] BIOCARDIA, INC. 2016 EQUITY INCENTIVE PLAN. RESTRICTED STOCK UNIT AGREEMENT . Unless otherwise defined herein, the terms defined in the BioCardia, Inc. 2016 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement (the “Award …May 30, 2023 · BioCardia has made significant progress in the development of its therapeutic candidates BCDA-01 and BCDA-02. Check out my recommendation on BCDA stock. 2023 BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023 24 Jul 2023 BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

書名：Price-Forecasting Models for Biocardia Inc BCDA Stock，ISBN：9798731444187，出版社： Independently published，作者：Ton Viet Ta，頁數：， ...The estimated Net Worth of David Mc Clung is at least $440 Thousand dollars as of 5 November 2018. Mr. Clung owns over 1,600 units of BioCardia stock worth over $5,952 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $434,495 as Chief Financial Officer at BioCardia.The estimated Net Worth of Simon H Stertzer is at least $673 millier dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $597,087 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.8 Nov 2023 ... Stock name: BCDA, Stock Code: BCDA, Company: BioCardia, Inc., Sector: Healthcare.BioCardia Inc (NASDAQ: BCDA) said the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase 3 pivotal CardiAMP Cell 

SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards …BioCardia Inc. Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings ...

BioCardia, Inc., headquartered in Sunnyvale, California, is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular ...Nov 26, 2023 · Website. n/a. 33. Peter Altman. https://www.biocardia.com. BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of ... BioCardia, Inc. Stock price Equities BCDA US09060U5074 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar Company Financials …The estimated Net Worth of Simon H Stertzer is at least $1.55 Миллион dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,476,667 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.Nov 16, 2023 · SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ... Convert BioCardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: BioCardia Inc (BCDAW) = 0.06 USD. Provided by Alpha Vantage. BioCardia Inc stock (BCDAW) in USD. 1 BCDAW = 0.06 USD. 1 month.Find the latest BioCardia, Inc. (BCDA) stock quote, history, news and other vital information to help you with your stock trading and investing.Convert Biocardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple. wise. Select a currency. USD. NASDAQ: Biocardia Inc ( BCDA) = 0.71 USD. Provided by Alpha Vantage.

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27% Nov-15-23 …

About the BioCardia Inc. stock forecast. As of 2023 November 17, Friday current price of BCDA stock is 0.790$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. BioCardia stock price has been showing a declining tendency so we believe that similar market segments were not very …

BioCardia, Inc. Common Stock (BCDA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Find the latest BioCardia, Inc. (BCDA) stock quote, history, news and other vital information to help you with your stock trading and investing. BioCardia currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the overall healthcare sector include Apellis Pharmaceuticals APLS, Avid Bioservices CDMO and Biohaven BHVN, also ...Nov 16, 2023 · BioCardia, Inc. announced a definitive agreement with a healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share in a registered direct offering. 8 Nov 2023 ... Stock name: BCDA, Stock Code: BCDA, Company: BioCardia, Inc., Sector: Healthcare.A high-level overview of BioCardia, Inc. (BCDA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.BioCardia (NASDAQ:BCDA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment?We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards …Jul 24, 2023 · July 24, 2023. SUNNYVALE, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase III pivotal CardiAMP ...

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE …BioCardia (NASDAQ:BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued. The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ...Instagram:https://instagram. courses to learn about investingis trading forex profitablebest futures contracts to tradenasdaq oncy David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018. currency trading bookswealth management consultant With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin. nyse cars On average, BioCardia executives and independent directors trade stock every 41 days with the average trade being worth of $320,009. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 16 December 2022, trading 595,238 units of BCDA stock currently worth $1,000,000.BioCardia Inc (NASDAQ: BCDA) said the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase 3 pivotal CardiAMP Cell